Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Teriflunomide (HMR1726)
DRUG
3 trials
Sponsors
Sanofi
Conditions
Multiple Sclerosis
Phase 2
Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Completed
NCT00228163
Sanofi
Multiple Sclerosis
Start: 2002-01-31
End: 2015-01-31
Updated: 2015-03-25
Phase 3
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
Completed
NCT00803049
Sanofi
Multiple Sclerosis
Start: 2006-10-31
End: 2015-12-31
Updated: 2017-01-30
Unknown Phase
An Observational Study on Teriflunomide-exposed Pregnancies
Completed
NCT03198351
Sanofi
Multiple Sclerosis
Start: 2013-04-25
End: 2023-06-13
Updated: 2023-08-28
Related Papers
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
Multiple Sclerosis Journal
2022-04-29
11 citations
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
2020-10-06
2 citations
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
Multiple Sclerosis Journal
2019-06-14
33 citations
068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study
Journal of Neurology Neurosurgery & Psychiatry
2018-05-24
6 citations
066 Impact of long-term teriflunomide treatment on lymphocyte counts and infections in pooled temso and tower studies
Journal of Neurology Neurosurgery & Psychiatry
2018-05-24
Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension Study (P6.389)
Neurology
2018-04-10
2 citations
Evaluation of the Long-term Treatment Effect of Teriflunomide on Cognitive Outcomes and Association With Brain Volume Change: Data From TEMSO and its Extension Study (P6.372)
Neurology
2018-04-10
1 citations
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
Neurology Neuroimmunology & Neuroinflammation
2017-06-29
21 citations
Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data (P3.038)
Neurology
2016-04-05
4 citations
Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results (P3.027)
Neurology
2016-04-05
1 citations
Predicting Treatment Response to Teriflunomide in the TEMSO Study Using the Modified Rio Score (P2.108)
Neurology
2016-04-05
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
2016-02-10
103 citations
12-Year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study (P7.223)
Neurology
2015-04-06
2 citations
Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms of Multiple Sclerosis: Update of the TEMSO Extension Trial (P3.150)
Neurology
2014-04-08
4 citations
Teriflunomide Treatment Is Not Associated With Increased Risk of Infections: Pooled Data From the Teriflunomide Development Program (P2.194)
Neurology
2014-04-08
4 citations